Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 5

Drug targets and predictive biomarkers in the management of metastatic melanoma

Authors Thumar, Giesen E, Kluger H

Received 12 May 2012

Accepted for publication 12 July 2012

Published 28 September 2012 Volume 2012:5 Pages 139—148

DOI https://doi.org/10.2147/PGPM.S25100

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4



Jaykumar Thumar, Eva Giesen, Harriet M Kluger

Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

Abstract: Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-4 antibody) and vemurafenib (mutant B-RAFV600E kinase inhibitor) by the Federal Drug Administration has led to a new era in melanoma treatment, and additional promising drugs and drug combinations are currently being investigated. As the choices of treatment for melanoma have expanded, the need to identify predictive biomarkers to tailor treatment strategies to individual tumor or immune system characteristics has become necessary. Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit. In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease.

Keywords: vemurafenib, mutations, inhibitors, tumors

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.